Netherlands· NL-9f174bd53c59
Strimvelis 1-10 miljoen cellen/ml dispersie voor infusie
A other immunostimulants product containing autologe hematopoëtische cd34+ stamcellen getransduceerd met retrovirale vector coderend voor de humane adenosine deaminase cdna sequentie, registered in Netherlands by Fondazione Telethon. The same ATC class is registered in 8 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Autologe hematopoëtische cd34+ stamcellen getransduceerd met retrovirale vector coderend voor de humane adenosine deaminase cdna sequentie is registered in 8 of 19 countries.
Countries holding a registration under ATC L03AX (other immunostimulants), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Autologe hematopoëtische cd34+ stamcellen getransduceerd met retrovirale vector coderend voor de humane adenosine deaminase cdna sequentie · ATC L03AX
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- AUTOLOGE HEMATOPOËTISCHE CD34+ STAMCELLEN GETRANSDUCEERD MET RETROVIRALE VECTOR CODEREND VOOR DE HUMANE ADENOSINE DEAMINASE CDNA SEQUENTIE
- Manufacturer
- Fondazione Telethon
- Country
- Netherlands (NL)
- ATC code
- L03AX
- ATC class
- Other immunostimulants
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/16/1097
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L03AX
Other immunostimulants, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b7a666d8-1736-4a9d-abb5-467a3c55d05b GET /v1/drugs/b7a666d8-1736-4a9d-abb5-467a3c55d05b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/strimvelis-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Other immunostimulants",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp117418",
"excipients": [
"NATRIUMCHLORIDE"
],
"substances": [
"AUTOLOGE HEMATOPOËTISCHE CD34+ STAMCELLEN GETRANSDUCEERD MET RETROVIRALE VECTOR CODEREND VOOR DE HUMANE ADENOSINE DEAMINASE CDNA SEQUENTIE"
],
"leaflet_url": null,
"authorised_at": "2016/05/26",
"procedure_number": "EMEA/H/C/003854",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/16/1097",
"additional_monitoring": "Y"
}See everything about autologe hematopoëtische cd34+ stamcellen getransduceerd met retrovirale vector coderend voor de humane adenosine deaminase cdna sequentie.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.